Perrigo (PRGO) Net Income towards Common Stockholders Growth (1y) (2013 - 2026)
Perrigo (PRGO) Net Income towards Common Stockholders Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Perrigo | 1.93 Bn | 1.53 Bn | 313.90 Mn | 985.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -78.48% |
| Mar 28, 2026 | -33.85% |
| Dec 31, 2025 | -16.67% |
| Sep 27, 2025 | -52.94% |
| Jun 28, 2025 | -192.59% |
| Mar 29, 2025 | -209.52% |
| Dec 31, 2024 | 34.78% |
| Sep 28, 2024 | -183.33% |
| Jun 29, 2024 | -440.00% |
| Mar 30, 2024 | -10.53% |
| Dec 31, 2023 | 58.18% |
| Sep 30, 2023 | -144.44% |
| Jul 1, 2023 | -150.00% |
| Apr 1, 2023 | -72.73% |
| Dec 31, 2022 | 51.11% |
| Oct 1, 2022 | 154.00% |
| Jul 2, 2022 | -100.37% |
| Apr 2, 2022 | -103.12% |
| Dec 31, 2021 | 81.68% |
| Oct 2, 2021 | 97.24% |